Camp4 Therapeutics Corp. SEC Filings

Vivo Opportunity funds disclosed ownership positions in Camp4 Therapeutics (CAMP). Together, Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC report beneficial ownership of 3,561,793 shares, representing 7.6% of the class based on a 46,878,487-share base that includes a 26,717,414-share private placement closed September 11, 2025. Separate Cayman entities, Vivo Opportunity Cayman Fund, L.P. and its GP, report beneficial ownership of 359,775 shares (0.8%). All reported shares are held of record by the named funds, and the filers state sole voting and dispositive power over the shares. The filing is a Schedule 13G indicating passive investment intent.

Coastlands-affiliated entities and Matthew D. Perry reported holding an aggregate of 4,886,722 shares of Camp4 Therapeutics Corp common stock. The filing lists that amount as representing 10.0% of the class on the cover sheets and as 9.99% in Item 4, reflecting the reporting persons' calculation based on 20,161,073 shares outstanding as of August 5, 2025 and an additional 26,681,053 shares issued in a private placement that closed September 11, 2025. Each reporting person disclaims beneficial ownership except to the extent of pecuniary interest and states the shares are held in the ordinary course of business and not to influence control of the issuer. All reporting persons show shared voting and dispositive power over the 4,886,722 shares and no sole voting or dispositive power.

Andrew J. Schwab, a director and 10% owner of Camp4 Therapeutics Corp (CAMP), reported an acquisition on Form 4. The filing shows a transaction dated 09/11/2025 in which 2,941,176 shares of common stock were acquired at $1.53 per share. The shares are reported as indirectly owned through 5AM Ventures VII, L.P. The filing also discloses additional indirect holdings attributed to related 5AM entities: 2,625,145 shares held by 5AM Ventures VI, L.P. and 302,770 shares held by 5AM Opportunities II, L.P. Explanatory footnotes state Schwab is a managing member of the general partner entities and disclaims direct beneficial ownership except to the extent of pecuniary interest.

Camp4 Therapeutics insider acquisition: Multiple 5AM-affiliated entities and Kush Parmar reported purchases and beneficial holdings of Camp4 Therapeutics (CAMP) common stock. On 09/11/2025 a purchase transaction (code P) was reported for 2,941,176 shares at $1.53 per share. The filing lists beneficial holdings following the transaction: 2,941,176 shares held by 5AM Ventures VII, L.P., 2,625,145 shares by 5AM Ventures VI, L.P., and 302,770 shares by 5AM Opportunities II, L.P. The reporting parties disclose indirect ownership through related general partner entities and state shared voting and investment power; the statements include disclaimers limiting beneficial ownership to pecuniary interest.

Camp4 Therapeutics Schedule 13D/A reports that Enavate Sciences GP, LLC and Everest Aggregator, LP each beneficially own 3,785,802 shares of Camp4 common stock, representing 8.1% of the class after a private placement. The amendment states the reported percentage is calculated using 20,161,073 shares outstanding as of August 5, 2025 plus 26,717,414 shares issued in a private placement that closed September 11, 2025. The filing clarifies that the change in reported percentage is due to dilution from the new issuance, not purchases or sales by the reporting persons, and discloses that James P. Boylan resigned from Camp4’s board effective September 9, 2025.

Camp4 Therapeutics amended a Schedule 13D to report participation by Polaris-related investors in a private placement and updated beneficial ownership figures. PP VII and PEF VII purchased 1,221,721 and 85,468 shares, respectively, at $1.53 per share on September 11, 2025, for aggregate amounts of $1,869,233.13 and $130,766.04.

The Purchase Agreement contemplates an Initial Closing issuing 26,681,053 shares and pre-funded warrants for 6,003,758 shares at $1.53 per share (pre-funded warrants at $1.5299). Management subscribed for additional small tranches at $1.65 per share, producing approximately $50.1 million of gross proceeds at the Initial Closing before fees. A Second Closing could issue up to 32,721,172 more shares/pre-funded warrants if a CTA milestone is met and either a $7.50 VWAP threshold is achieved or investors holding a majority waive the price condition. A Registration Rights Agreement obligates the issuer to register the resale of the issued shares and underlying warrant shares.

Polaris-related investors purchased shares of Camp4 Therapeutics in a private placement on September 11, 2025. Polaris Partners VII, L.P. and Polaris Entrepreneurs' Fund VII, L.P. acquired common stock at $1.53 per share under a Securities Purchase Agreement dated September 9, 2025. Reported purchases include 1,221,721 shares and 85,468 shares respectively. After the transactions, the filing shows beneficial holdings attributed indirectly to Polaris entities totaling 2,825,500 shares, 197,661 shares, and an additional 909,090 shares held by related Polaris funds or entities. Multiple Polaris-affiliated entities and named managing members disclaim beneficial ownership except for pecuniary interests.

Camp4 Therapeutics insider purchases reported by director and 10% owner Nashat Amir. On 09/11/2025 Polaris-affiliated entities purchased shares in a private placement at $1.53 per share under a Securities Purchase Agreement dated 09/09/2025. Purchases reported include 1,221,721 shares by Polaris Partners VII, L.P. and 85,468 shares by Polaris Entrepreneurs' Fund VII, L.P., with combined reported beneficial ownership following the transactions shown as 2,825,500 and 197,661 shares respectively and an additional 909,090 shares held indirectly by Polaris Partners X, L.P.

The filing discloses indirect ownership through management entities and contains standard disclaimers that the managing entities and reported persons disclaim beneficial ownership except to the extent of pecuniary interests.